BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
2.380 USD    0.00%
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Biotech Reaffirms 2021 Revenue Target

12/29/2021 | 04:11am EDT


© MT Newswires 2021
All news about BURNING ROCK BIOTECH LIMITED
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
05/16Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form ..
PU
03/22Burning Rock Biotech Limited Reports Earnings Results for the Full Year Ended December ..
CI
03/22TRANSCRIPT : Burning Rock Biotech Limited, Q4 2021 Earnings Call, Mar 22, 2022
CI
03/22Burning Rock Biotech's Q4 Loss Widens, Revenue Rises
MT
03/21BURNING ROCK BIOTECH : Q4 2021 Presentation Slides
PU
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Biotech Limited Provides Revenue Guidance for the Year 2022
CI
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2022 620 M 92,5 M 92,5 M
Net income 2022 -656 M -97,9 M -97,9 M
Net cash 2022 673 M 100 M 100 M
P/E ratio 2022 -2,56x
Yield 2022 -
Capitalization 1 677 M 250 M 250 M
EV / Sales 2022 1,62x
EV / Sales 2023 0,49x
Nbr of Employees 1 394
Free-Float 67,9%
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 15,94 CNY
Average target price 84,82 CNY
Spread / Average Target 432%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Technology Officer
Wendy Hayes Independent Director
Sector and Competitors